Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/53565
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYue Qiuen_US
dc.contributor.authorYan Zhaoen_US
dc.contributor.authorFei Liuen_US
dc.contributor.authorBo Yeen_US
dc.contributor.authorZhenjun Zhaoen_US
dc.contributor.authorSataporn Thongpoonen_US
dc.contributor.authorWanlapa Roobsoongen_US
dc.contributor.authorJetsumon Sattabongkoten_US
dc.contributor.authorLiwang Cuien_US
dc.contributor.authorQi Fanen_US
dc.contributor.authorYaming Caoen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMorsani College of Medicineen_US
dc.contributor.otherChina Medical University Shenyangen_US
dc.contributor.otherDalian Institute of Biotechnologyen_US
dc.date.accessioned2020-03-26T04:29:55Z-
dc.date.available2020-03-26T04:29:55Z-
dc.date.issued2020-03-17en_US
dc.identifier.citationVaccine. Vol.38, No.13 (2020), 2841-2848en_US
dc.identifier.issn18732518en_US
dc.identifier.issn0264410Xen_US
dc.identifier.other2-s2.0-85079861419en_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/53565-
dc.description.abstract© 2020 The Author(s) Transmission-blocking vaccine (TBV) is a promising strategy to interfere with the transmission of malaria. To date, only limited TBV candidate antigens have been identified for Plasmodium vivax. HAP2 is a gamete membrane fusion protein, with homology to the class II viral fusion proteins. Herein we reported the characterization of the PvHAP2 for its potential as a TBV candidate for P. vivax. The HAP2/GCS1 domain of PvHAP2 was expressed in the baculovirus expression system and the recombinant protein was used to raise antibodies in rabbits. Indirect immunofluorescence assays showed that anti-PvHAP2 antibodies reacted only with the male gametocytes on blood smears. Direct membrane feeding assays were conducted using four field P. vivax isolates in Anopheles dirus. At a mean infection intensity of 72.4, 70.7, 51.3, and 15.6 oocysts/midgut with the control antibodies, anti-PvHAP2 antibodies significantly reduced the midgut oocyst intensity by 40.3, 44.4, 61.9, and 89.7%. Whereas the anti-PvHAP2 antibodies were not effective in reducing the infection prevalence at higher parasite exposure (51.3–72.4 oocysts/midgut in the control group), the anti-PvHAP2 antibodies reduced infection prevalence by 50% at a low challenge (15.6 oocysts/midgut). Multiple sequence alignment showed 100% identity among these Thai P. vivax isolates, suggesting that polymorphism may not be an impediment for the utilization of PvHAP2 as a TBV antigen. In conclusion, our results suggest that PvHAP2 could serve as a TBV candidate for P. vivax, and further optimization and evaluation are warranted.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85079861419&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.subjectVeterinaryen_US
dc.titleEvaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidateen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1016/j.vaccine.2020.02.011en_US
dc.identifier.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85079861419&origin=inwarden_US
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.